Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.
Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.
-
Clinical Trial Information
Trial Contact: Tilme, Linda; Beltran, Yajira
Trial Phone: 321.843.5278 ; 321.841.7619
-
IRB No: 18.037.03
Protocol Abbrev: MARC35-6 Year
Principal Investigator: Federico Ricardo Laham, MD
Age Group: Pediatric
Secondary Protocol No: MARC35-6 Year
Treatment: Exam and speciman collection
-
Objective
Aim 1. To investigate the relation of the airway microbiome to risk of childhood asthma among infants with severe bronchiolitis (MARC-35).
Aim 2. To investigate the relation of longitudinal patterns of the airway microbiome (e.g., infancy, age 3y, and age 6y) to the risk of childhood asthma in the MARC-35 and MARC-43 cohorts combined. MARC-43 is a separate cohort of children enrolled as healthy infants; it is funded by UG3OD023253 and covered by a separate IRB application at sites involved.
Aim 3. To identify nasal airway microRNAs that are prospectively associated with asthma at age 6 years.
Aim 4. To compare asthma cases vs non-cases on downstream NFκB signaling mediators and outcomes associated with nasal airway microRNAs.
Aim 5. To derive asthma endotypes at age 6 years. By integrating microRNA expression, NFκB signaling mediators and outcomes, and asthma phenotyping data from the age 6-year examination, we will determine asthma endotypes with the use of an innovative systems-based approach. -
Key Eligibility
▪ Previously enrolled in MARC-35 42-Month
▪ Age 6.0 (age 72 months) to 7.9 years (age 95 months) of age at the time of the inperson exam
▪ Ability of the parent/legal guardian to give informed consent
